natgillin/translations-raw huggingface dataset:
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Dutrebis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Fasturtec can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ebilfumin findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ebilfumin can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ebymect findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ebymect can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Edistride findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Edistride can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Elocta findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Elocta can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Entyvio findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Entyvio can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Envarsus findes på agenturets websted underema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Envarsus can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Episalvan findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Episalvan can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Eptifibatide Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Eptifibatide Accord can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Evotaz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Evotaz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Exviera findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Exviera can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Farydak findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Farydak can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Feraccru findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Feraccru can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Fexeric findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Fexeric can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Gardasil 9 findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Gardasil 9 can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Genvoya findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Genvoya can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Granupas findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Granupas can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Harvoni findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Harvoni can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Hemangiol findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Hemangiol can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Hetlioz findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Hetlioz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Holoclar findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Holoclar can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Iblias findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Iblias can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ikervis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ikervis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Imbruvica findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Imbruvica can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Imlygic findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Imlygic can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Incruse findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Incruse can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Intuniv findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Intuniv can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ionsys findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ionsys can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ivabradine Anpharm findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ivabradine Anpharm can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Izba findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Izba can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Jardiance findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Jardiance can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Kanuma findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Kanuma can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Kengrexal findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Kengrexal can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ketoconazole HRA findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ketoconazole HRA can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Keytruda findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Keytruda can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Kolbam findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Kolbam can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Kovaltry findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Kovaltry can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Kyprolis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Kyprolis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Lenvima findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Lenvima can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Lixiana findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Lixiana can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Lumark findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Lumark can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Lymphoseek findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Lymphoseek can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Lynparza findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Lynparza can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Mekinist findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Mekinist can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Mirvaso findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Mirvaso can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Moventig findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Moventig can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Mysimba findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Mysimba can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Neofordex findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Neofordex can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Nivolumab BMS findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Nivolumab BMS can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Nucala findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Nucala can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Numient findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Numient can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Nuwiq findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reportss.
The full EPAR and risk management plan summary for Nuwiq can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Obizur findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Obizur can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Odomzo findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Odomzo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Ofev findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Ofev can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Olysio findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Olysio can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Omidria findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Omidria can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Oncaspar findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Oncaspar can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Opdivo findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Opdivo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Orbactiv findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Orbactiv can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Orkambi findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Orkambi can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Otezla findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Otezla can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed Accord findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pemetrexed Accord can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed Fresenius Kabi findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR for Pemetrexed Fresenius Kabi can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed Hospira findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pemetrexed Hospira can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed Lilly findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pemetrexed Lilly can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Pemetrexed medac findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Pemetrexed medac can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.